Pegloticase

Peglotigase which is a PEGylated uric acid specific enzyme obtained from genitically modified mammalin urate oxidase(uricase) which achieves it therapeutic effect by catalyzing the oxidation of uric acid to allantoin, thereby lowering serum uric acid.


Brands
Adult Dose
Dose: 8 to 8 mg
Single Dose: 8 (8)
Frequency: As recommended.
Route: IV
Instructions: Pegloticase should be administered Every 2 weeks._x000D_Dilute solution Pegloticase to reach Room Temperature._x000D_Donot institute Pegloticase therapy with oral urate lowering agents._x000D_donot Administer as IV push or Bolus_x000D_Administer IV infusion over no less than 120minutes via gravity feed, syringe type pump or infusion pump_x000D_Monitor serum Uric Acid Level
Neonatal
Paedriatic
Characteristics
. It is of Synthetic origin and belongs to Pegylated Uric acid Enzyme. It belongs to Uric Acid Lowering Agent pharmacological group on the basis of mechanism of action. The Molecular Weight of Pegloticase is 540.00.
Contraindications
Pegloticase is contraindicated in conditions like G6pd deficiency.
Effects
The severe or irreversible adverse effects of Pegloticase, which give rise to further complications include Congestive heart failure.Pegloticase produces potentially life-threatening effects which include Anaphylaxis. which are responsible for the discontinuation of Pegloticase therapy.The symptomatic adverse reactions produced by Pegloticase are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dyspnea, Constipation, Urticaria, Pruritus, Erythema, Nausea and vomiting, Chest pain, Ecchymoses, Infusion reactions, 1st dose, Nasopharyngitis, gout flares, contusion.
Indications
Pegloticase is primarily indicated in conditions like Asymptomatic Hyperuricemia, Gout.
Interactions
No data regarding the interactions of Pegloticase was found.
Interfrence
Risks
If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Warnings
pegloticase should be administered by a healthcare provider. patient should be pre medicated with Antihistamines and Cortico steroids. Patient should be closely monitored for Anaphylaxis. Monitor Serum Uric Acid level prior to infusion , Discontinue treatment if level increase to above 6mg/dl. monitor closely for sign and symptoms of infusion reaction. Excercise caution in patient who have Congestive heart failure.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.